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SulTlmary 
Clinical isolates of primate immunodeficiency viruses, including human immunodeficiency vi- 
rus type 1 (HIV-1), enter target cells by sequential binding to CD4 and the chemokine recep- 
tor CCR5, a member of the seven-transmembrane receptor family. HIV-1 variants which use 
additional chemokine receptors are present in the central nervous system or emerge during the 
course of infection. Simian immunodeficiency viruses (SIV) have been shown to use CCR5 as 
a coreceptor, but no other receptors for these viruses have been identified. Here we show that 
two orphan seven-transmembrane segment receptors, gprl and gpr15, serve as coreceptors for 
SIV, and are expressed in human alveolar macrophages. The more efficient of these, gpr15, is 
also expressed in human CD4 + T  lymphocytes and activated rhesus macaque peripheral blood 
mononuclear cells. The gpr15 and gprl proteins lack several hallmarks ofchemokine receptors, 
but share with CCR5 an amino-terminal motif rich in tyrosine residues. These results under- 
score the potential diversity of seven-transmembrane segment receptors used as entry cofactors 
by primate immunodeficiency viruses, and may contribute to an understanding of viral varia- 
tion and pathogenesis. 
T 
he  human  immunodeficiency  viruses,  HIV-1  and 
HIV-2, induce  acquired  immunodeficiency syndrome 
(AIDS)  in  humans,  and  simian immunodeficiency viruses 
(SIV) 1 can induce AIDS-like illness in Old World monkeys 
(1-5).  Isolates of HIV-1, the major cause of AIDS in hu- 
mans, have been phylogenetically segregated into groups M 
and O  (6).  HIV-2 and SIV form a distinct group of phylo- 
genetically and antigenically related viruses (2, 3, 6-8). 
AIDS induced by HIV-1 or HIV-2 in humans or by SIV 
in monkeys is characterized by the  depletion  of CD4 + T 
lymphocytes, which represent a major target of viral infec- 
tion in vivo (9).  Infection of other CD4 + cell types, such as 
tAbbreviations used in this paper: 7-TMS, seven-transmembrane  segment; 
CAT, chloramphenicol acetyltransferase; SIV, simian immunodeficiency 
virus. 
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monocytes in the blood, tissue macrophages, and microglial 
cells  in  the brain,  has been suggested to be important for 
the  pathogenesis  of primate  immunodeficiency viruses in 
the central nervous system and in the lungs  (10-14).  Cer- 
tain populations of dendritic  cells in the blood and tissues 
may also be infected by these viruses (15,  16). 
The  tropism  of primate  immunodeficiency viruses  for 
CD4 + cells is explained by the use of the CD4 glycopro- 
tein as a primary receptor for virus entry into the cell (17- 
19).  The viral envelope glycoproteins, which mediate virus 
entry, consist of the gpl20 exterior envelope glycoprotein 
and  the  gp41  transmembrane  glycoprotein  (20,  21).  The 
gp120  glycoprotein  binds  the  CD4  molecule,  following 
which the gp120-CD4 complex binds one of the members 
of the  chemokine receptor subgroup  of seven-transmem- 
brahe segment (7-TMS) receptors (22-24).  This binding is 
believed to promote conformational changes in the gp120 
and gp41  glycoproteins which  result in the fusion of viral 
and cellular membranes (25-27). 
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coprotein sequences (28,  29),  dictates the specific chemo- 
kine receptor which can be used as an entry cofactor. M-tropic 
HIV-1 variants which use the chemokine receptor CCR5 
as  a  coreceptor  predominate  during  the  asymptomatic 
stages of infection (30-35). CCR5 is expressed on T  lym- 
phocytes, monocytes/macrophages, brain microglia, and den- 
dritic cells (36-39).  Individuals with defects in CCR5 ex- 
pression are  relatively resistant to  HIV-1  infection (40-42), 
indicating the  critical contribution of this  chemokine re- 
ceptor to virus transmission. Some M-tropic brain isolates 
of HIV-1  also  use  the  chemokine  receptor  CCR3  as  a 
coreceptor,  consistent with  the  expression  of CCR3  in 
brain microglia (39). Later in the course of infection, T-tropic 
HIV-1  variants emerge  which  can use  chemokine recep- 
tors, especially CXCR4, but also CCR3 and CCR2b, in ad- 
dition to CCR5  (34, 35, 43-45). The emergence of these 
viruses has been suggested to coincide with a less favorable 
clinical prognosis (45), perhaps through an expansion of the 
range ofinfectable CD4 ÷ T  cell subsets (46). 
Primary isolates of HIV-2 and SIV have been shown to 
use rhesus macaque or human CCR5  as a coreceptor (47, 
48) and are inhibited by the natural CCR5 ligands, MIP-loq 
MIP-113,  and RANTES  (49).  None of the  other known 
HIV-1  coreceptors  has  been  shown  to  be  used  by  SIV, 
whereas some isolates of HIV-2 can use CXCR4 for entry 
into CD4-  cells (50).  Several lines of evidence have sug- 
gested  the  existence  of at  least  one  other  coreceptor  for 
SIV. A  human B  cell/T cell hybrid, CEM×174,  supports 
SIV entry, but lacks CCR5 and does not support efficient 
entry of HIV-1 viruses using CCR5  (48). A  neuroglioma 
cell line, U87, stably transfected with CD4, similarly sup- 
ports  entry of SIVmac239 but does  not allow for  efficient 
entry  of any  known  HIV-1  virus  (51).  Finally, PBMCs 
from  humans  lacking  a  functional  CCR5  receptor  can 
nonetheless be  infected with  SIV  (48).  Here  we  identify 
two additional SIV coreceptors, gprl and gprl5, which are 
expressed in U87 and CEM× 174 cells, respectively. Both 
proteins are expressed in human alveolar macrophages, and 
the  gpr15  protein is  also  expressed  in CD4  +  T  lympho- 
cytes. 
Materials  and  Methods 
Preparation of cDNA Libraries and eDNA.  Messenger RNA was 
isolated using the CsC1 method and selection on magnetic beads 
with oligo-dT (Dynabeads;  DYNAL,  Inc., Lake  Success, NY). 
RNA was obtained from purified human CD4 + peripheral blood 
T cells (gift of Dr. Linch Clayton, Dana-Farber Cancer Institutes, 
Boston, MA), human alveolar macrophages (gi~ of Dr.  Hat Chap- 
man, Brigham and Women's Hospital, Boston, MA), CEMX 174 
cells, and U87 neuroglioma cells. RNA was  also isolated  from 
phytohemagglutinin-treated,  interleukin-2--stimulated  PBMCs 
from a healthy rhesus macaque (New England Regional Primate 
Research Center, Foxboro, MA). The cDNA libraries from the 
U87 and CEMN 174 cell lines were made by reverse transcription 
(Superscript; GIBCO BILL, Gaithersburg, MD)  using a unidirec- 
tional primer supplied by the  manufacturer.  Size-selected cDNAs 
were cloned into a BstXI/NotI-digested pcDNA3.1 vector (In- 
vitrogen, Carlsbad, CA). The human alveolar macrophage library 
was prepared by Invitrogen in pcDNA1. Double-stranded CD4  ÷ 
T cell cDNA was synthesized using a kit from Boehringer Mann- 
helm (Indianapolis, IN). 
Cloning of cDNAs for 7- TMS Proteins.  The  expression  plas- 
mids for rdcl, ebi2, gprl, gpr15, and dez were prepared by PCR 
amplification of a cDNA library made from either CEM× 174 or 
U87 cells, as described above. The amplified fragments were cloned 
into the pcDNA3 plasmid for expression. Expression plasmids for 
other chemokine receptors were generously supplied by Drs. Paul 
Ponath and Walter Newman (LeukoSite,  Inc., Cambridge, MA) 
(v28,  CXCR1,  CXCR2),  Dr. Elliot  Kieff (Harvard  Medical 
School,  Boston, MA)  (ebil), and Dr. Monica Napolitano (Re- 
gina Elena Cancer Institut, Rome, Italy) (terl). 
Testing SIV Coreceptor  Activity.  A  previously  described  env- 
complementation method (27, 28, 47) was used to produce re- 
combinant HIV-1  viruses  which  contained the  SIV  envelope 
glycoproteins and  were  capable  of encoding chloramphenicol 
acetyltransferase (CAT) in target cells. Briefly, recombinant virus 
was  incubated with  Ct2Th  cells transfected  with plasmids  ex- 
pressing human CD4 and candidate  coreceptors.  Cells were har- 
Table 1.  Expression  of 7-TMS Proteins and Activity as an 
SIV,~ac23 9 Coreceptor 
Expression  in: 
Primary  SIVm~c239 
7-TMS  CD4  +  coreceptor 
protein  Reference  CEM× 174  U87  T cells  activity 
apj  55  -  -  -  ND 
blrl  56  +  -  ND  - 
CCR5  38, 57  -  -  +  + 
CXCR1  58  ND  ND  ND  - 
CXCR2  59  ND  ND  ND  -- 
CXCR3  60  ND  ND  ND  - 
CXCR4  61  +  +  +  - 
dez  62  -  +  +  - 
ebil  63  +  +  +  - 
ebi2  63  +  +  +  - 
gc96  *  --  -  +  ND 
gcy4  64  --  -  +  ND 
gprl  53  -  +  -  + 
gpr2  53  -  --  --  ND 
gpr4  65  --  -  +  ND 
gpr5  65  -  -  -  ND 
gpr15  54  +  -  +  + 
rdcl  66  +  +  +  - 
terl  67  +  -  +  - 
v28  68  ND  ND  ND  - 
Positive expression values indicate the detection of a PCR product of 
expected size and restriction map amplified from the indicated eDNA 
source. Coreceptor activity for viruses with SIVmac239 envelope glyco- 
proteins was determined as described in Materials and Methods. 
*These sequence data are available  from EMBL/GenBank/DDBJ un- 
der accession number U45982. 
406  New SIV Coreceptors Figure 1.  CAT activity in Cf2Th cells expressing CD4 alone or together with gprl, gpr15, CCR5, or CXCR4 after incubation with HIV-1 recombi- 
nant viruses carrying the SIVm~c239,  SIVn~316, or HIV-1 (YU2, HXBc2, 89.6, or ADA) envelope glycoproteins. A representative experiment is shown. 
The amount  of target cell lysate used was equivalent for all the experiments shown. CAT activity was determined by calculating the percentage of 
chloramphenicol present in acetylated forms (three uppermost spots) to the total amount of chloramphenicol. The nonacetylated form of chloramphenicol is 
present in the spot closest to the origin, which is near the bottom of the figure. 
vested and assayed for CAT activity, which was determined by 
measuring the conversion of chloramphenicol to acetylated forms 
of chloramphenicol. The SIVmac239 and SIVm~c316 envelope gly- 
coproteins were expressed from the previously described pS1VAgpv 
plasmid (47). The HIV-1 envelope glycoproteins were expressed 
as previously described (27, 28). 
Analysis  of Expression  of 7-TMS  Proteins in  Cells and  Tissues. 
The  expression of 7-TMS  protein messenger RNA  in  CEM× 
174 and U87 cells and primary human CD4 + T lymphocytes and 
alveolar macrophages was examined by synthesis of cDNA from 
polyadenylated  RNA prepared from these cells, as described above. 
Primers corresponding to the nucleotide sequences encoding the 
first and  third extracellular loops of the proteins were  used for 
amplification by PCR.  The identity of amplified fragments was 
confirmed by restriction enzyme digestion. 
lope glycoproteins and expressed CAT were incubated with 
Cf2Th  canine  thymocytes  transfected  with  plasmids  ex- 
pressing human CD4 and the 7-TMS proteins. Table 1 lists 
the 7-TMS proteins tested, summarizes their expression in 
CEM× 174,  U87,  and human CD4 + T  cells, and indicates 
coreceptor activity for viruses with the SIVmac239  envelope 
glycoproteins.  Of the  7-TMS  proteins  tested,  only  gprl, 
gpr15,  and CCR5  supported the entry of viruses with the 
Table 2.  CA T Activity in Cf2Th  Cells Expressing CD4 and 
7-TMS Proteins  following Incubation with  Viruses Containing 
Different Envelope Glycoproteins 
Viral envelope glycoproteins 
SIV  HIV-1 
Results 
We  had previously tested a  number  of human  chemo- 
kine  receptors  (CCR1-CCR5,  as  well  as  CXCR4)  and 
found that of these only CCR5  could support entry of an 
HIV-1  virus pseudotyped with the envelope glycoproteins 
of a  pathogenic,  molecularly cloned SIV,  SIVmac239  (47). 
TO identify additional coreceptors which might be used by 
SIV, we screened cDNA libraries from SIV-infectable cells, 
CEM×  174 and U87, for the expression ofmRNA  encod- 
ing known 7-TMS proteins exhibiting some sequence sim- 
ilarity to  chemokine  receptors.  The  cDNAs  which  were 
shown  to  be  expressed in  either cell line were  tested for 
the ability to support SIV and HIV-1  entry. Recombinant 
HIV-1 viruses which contained either HIV-1 or SIV enve- 
7-TMS protein SIVmac239 SIV~ac316  ADA  YU2  JR-FL  89.6 
CXCR4  <0.1  <0.1  <0.1  <0.1  <0.1  9.3 
CCR5  19.0  12.1  113.9290.8  203.7  9.4 
~rl  7.0  2.7  <0.1  <0.1  <0.1  <0.1 
~r15  30.3  30.5  0.7  0.9  <0.1  <0.1 
The  percent  conversion  of chloramphenicol  to  acetylated  forms  is 
shown following incubation  of comparable amounts of lysates derived 
from Cf2Th  cells exposed to recombinant  viruses. The CAT activity 
was calculated as described in the legend to Fig. 1. In some cases, dilu- 
tions of the lysates were tested to bring the assay  within the linear range 
and, thus, the reported values exceed 100%. 
407  Farzan et al. glorl5 
gprl 
rCCR5 
CCR5 
MDPEETSVYLDYYYATSP_N 
MEDLEETLFEEFENYSYDLDYYSLESD 
MDYQVSSPTYDIDYYTSE_£PC 
MDYQVSSPIYDINYYTSEPC 
Figure  2.  Expression  ofgprl and gpr15 RNA in cells. The cDNA li- 
braries from U87 and CEM×174 cells and from human alveolar mac- 
rophages, as well as cDNA prepared from human CD4  + T lymphocytes, 
were PCR amplified using gprl- or gpr15-specific  primers. 
SIVmac239  envelope  glycoproteins.  These  three  7-TMS 
proteins also supported the entry of viruses with the mac- 
rophage-tropic SIVmac316 envelope glycoproteins (Fig.  1). 
The SIV coreceptor activity exhibited by the gpr15 protein 
was greater than that of CCR5, whereas the coreceptor ac- 
tivity of gprl was ~30% that of CCR5  (Table 2). Most of 
the  viruses with  HIV-1  envelope glycoproteins  (HXBc2, 
JP,.-FL,  89.6)  did  not  infect  Cf2Th  cells  expressing  CD4 
and gpr15, although the viruses with the M-tropic HIV-1 
ADA and YU2 envelope glycoproteins demonstrated a low 
but reproducible signal in these cells  (Fig.  1 and Table 2). 
Following incubation with the ADA and YU2 viruses, the 
CAT  conversion  in  the  CD4 +,  gpr15 +  Cf2Th  cells  was 
<1% of that seen in the CD4  +,  CC1<5 + control cells  (Ta- 
ble 2).  Cf2Th cells  expressing CD4 and gprl  were not in- 
fected  by viruses  containing  any  of the  HIV-1  envelope 
glycoproteins tested (Table 2). 
The expression of gpr15 and gprl  in different cell types 
was examined.  Since specific reagents to detect these pro- 
teins were not available, expression was examined by R.NA 
analysis.  A cDNA for gpr15 was readily detected in human 
CD4 + T  lymphocytes, in human alveolar macrophages, in 
activated rhesus macaque PBMCs, and in CEMX 174 cells, 
but not in U87 cells  (Table 1, Fig. 2, and data not shown). 
By contrast, a cDNA for gprl could not be detected in pri- 
mary  human  T  lymphocytes,  activated  rhesus  macaque 
PBMCs, or CEM× 174 cells, but was detected in U87 cells 
and human alveolar macrophages. 
Discussion 
HIV-1, HIV-2, and SIV all use CCR.5  as a coreceptor, 
indicating the importance of this protein in primate immu- 
nodeficiency virus pathogenesis  (28,  30-33,  47,  48).  The 
use of other chemokine receptors by HIV-1 has been sug- 
gested to be important for infection of anatomical compart- 
ments such as the brain or for more efficient T  cell deple- 
tion  (39,  45,  46).  The identification  ofgprl  and gpr15  as 
additional  SIV  coreceptors  should  assist  efforts  to  under- 
stand the consequences of the use ofcoreceptors other than 
CCR5 in primate models of AIDS. While the in vivo con- 
tribution of gprl5  to  SIV replication  and pathogenesis re- 
quires further investigation, several lines of evidence indi- 
Figure  3.  An alignment of human gprl, human gprl5, rhesus CCR5 
(rccrS), and human CCR.5 from  the NH2-terminus  through the first cys- 
teine of CCR5 is shown. Tyrosines shown to be important for HIV-1 
and SIVm~c239 entry are shown in bold. Other residues similarly posi- 
tioned in these proteins are underlined. Sequences for gprl and gpr15 are 
provided in references  53 and 54, respectively. 
cate that gpr15 is an important SIV coreceptor. The gprl5 
protein is expressed on CD4 + T  lymphocytes, a major tar- 
get cell for SIV infection in vivo (10),  and on alveolar mac- 
rophages.  The  gpr15 protein is  also expressed on  CEM× 
174 cells, which are routinely used to passage SIV obtained 
from monkey PBMCs  (52).  The  rapid outgrowth  of SIV 
viruses with minimal sequence changes on CEM× 174 cells 
suggests that these cells  express a receptor used by primary 
SIV viruses. The weak use ofgprl5 by the ADA and YU2 
HIV-1 viruses may be an inadvertent consequence of simi- 
larities in the amino-terminal regions of gprl5 and CCR5, 
or may indicate  that  adaptation  to  these  receptors or to  a 
related receptor occurs in some subsets ofHIV-1. 
The in vivo contribution of gprl to primate immunode- 
ficiency virus infection is also unresolved. The gprl protein 
weakly supported  SIV  infection  in  our  studies.  Whether 
this inefficient coreceptor activity is an intrinsic property of 
gprl  or merely reflects low cell surface expression of gprl 
requires further investigation. While gprl is not apparently 
expressed on  primary CD4 + lymphocytes, it  is  expressed 
on tissue macrophages and in the brain  (53)  and thus may 
play a role in SIV infection of particular nonlymphoid tar- 
get cells. 
In primary structure, gprl and gpr15 resemble the angio- 
tensin  II  receptor  and  the  orphan  receptors  dez  and  apj 
more than they do any of the known chemokine receptors 
(53,  54).  Gpr15,  like  dez  and  gprl,  lacks  the  cysteines in 
the  NH2-terminal region  and  the  third  extracellular loop 
which,  in the  chemokine receptors,  are thought to be di- 
sulfide linked.  It is interesting that  despite  the  general se- 
quence divergence of gprl5/gprl  and other identified pri- 
mate immunodeficiency virus coreceptors the gpr15 and gprl 
amino  termini  contain  three  tyrosines  which  align  with 
similarly positioned tyrosines in CCR5  (Fig.  3). Alteration 
of these tyrosines has been shown to decrease the efficiency 
with which CCR5 supports the entry of SIV and M-tropic 
HIV-1 isolates (Farzan, M., H. Choe, andJ.  Sodroski, un- 
published  observations).  The  identification  of gpr15  and 
gprl  as SIV coreceptors suggests a greater range and com- 
plexity  of coreceptors  for the  primate  immunodeficiency 
viruses  than  previously described.  Comparative studies  of 
these  divergent  coreceptors  with  the  known  coreceptors 
for these viruses should assist in the identification of com- 
mon structural elements in 7-TMS proteins which serve as 
viral entry cofactors. 
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